BIOHAVEN LTD (BHVN) Stock News
NYSE:BHVN - New York Stock Exchange, Inc. - VGG1110E1079 - Common Stock - Currency: USD
BHVN Latest News, Press Relases and Analysis
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are...
Why Is Biohaven Stock Falling On Thursday?
Biohaven secures $250 million from Oberland Capital, with total cash reaching $518 million to support troriluzole launch and operations.
Why BioHaven Stock Is Soaring Today
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are...
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and...
AppLovin's Valuation Reflects High Expectations For Monetization Expansion: Analyst
Needham analyst Bernie McTernan reiterated its Hold rating on AppLovin Corp. (NASDAQ:APP) on Wednesday. AppLovin’s primary tool for future growth is Axon 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds. In McTernan’s third AppLovin Ecommerce Tracker, the total number of websites in his sample using Axon grew by +3% compared to last month to 323, which includes 18 gross adds and 7 churns. Also Read: AppLovin’s Rapi
Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class
Optimized subcutaneous (SC) administration of BHV-1400 achieved rapid, deep, selective, and sustained lowering of Gd-IgA1, differentiating Biohaven's leading...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors
BHV-1510, a highly differentiated Trop2 ADC incorporating the proprietary TopoIx payload, demonstrates early clinical activity and favorable safety profile in...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
Stocks Rise Pre-Bell as Traders Assess Latest Economic Data, Fed Chair Remarks
The benchmark US stock measures were pointing higher before the open Friday as traders digest the la
Institutional investors juggle bitcoin ETF holdings, US filings show
(Reuters) -A number of high-profile asset managers cut their stakes in spot bitcoin exchange-traded funds amid a 12% drop in the cryptocurrency's price in the first quarter of 2025, according to recent regulatory filings. This marks a shift from previous quarters when asset managers had typically increased their holdings in spot bitcoin ETFs, as shown in previous quarterly 13-F filings with the Securities and Exchange Commission. Spot bitcoin ETFs, which made their market debut in January 2024, now paint a more complex picture.
Why Biohaven Stock Dove by Nearly 20% on Thursday
Volatile biotech stock Biohaven (NYSE: BHVN) is prone to sharp movements both up and down. After market close on Wednesday, Biohaven divulged that the U.S. Food and Drug Administration's (FDA) Division of Neurology 1 is extending the due date for its decision on a very promising pipeline drug developed by the company. Specifically, the FDA unit is extending the Prescription Drug User Fee Act (PDUFA) date for Biohaven's troriluzole, a treatment that targets brain disorder spinocerebellar ataxia (SCA), by three months.
Why Biohaven Stock Dove by Nearly 20% on Thursday
Why Is Biohaven Stock Falling On Thursday?
Biohaven Ltd. (NYSE:BHVN) shares plunged on Thursday after the Food and Drug Administration (FDA) unexpectedly delayed the review date for its rare-disease drug troriluzole. The Division of Neurology 1 within FDA’s Office of Neuroscience informed Biohaven that they are extending the PDUFA date for the troriluzole new drug application (NDA) for spinocerebellar ataxia (SCA) by three months to provide time for a full review of Biohaven’s recent submissions related to information requests from the F
Biohaven Plunges On A Surprise FDA Twist For Its Rare-Disease Drug
The company hadn't expected an advisory committee meeting, nor a three-month pushback for its rare-disease drug review.
FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced that the Division of Neurology 1 within FDA's Office of Neuroscience...
Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments
Cash, cash equivalents, marketable securities and restricted cash as of April 30, 2025 totaled approximately $518 million. Announced up to $600 million...
MoneyPass ATMs near me: How to find one
Here’s how to find the nearest ATM in MoneyPass’s fee-free ATM network.
Why BioHaven Stock Is Soaring Today
Shares of Biohaven (NYSE: BHVN) are surging on Monday. The move comes as the S&P 500 traded mixed and the Nasdaq Composite drifted slightly higher. Shares of the clinical-stage biopharmaceutical company were rising after Biohaven announced a $600 million non-dilutive financing deal with Oberland Capital.
Biohaven Announces Investment up to $600 Million by Oberland Capital
/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development...
Biohaven share price undervaluing pipeline potential, says RBC Capital
RBC Capital points out that notes released by the European Medicines Agency’s CHMP indicated that Biohaven (BHVN) had withdrawn the application for troriluzole in spinocerebellar ataxia. Investor sentiment has been more bearish lately, with most believing that SCA approval in the U.S. is critical to helping the stock recover, notes the firm, which believes this news “puts additional pressure” on that and explains the outsized stock move. However, it also believes the EMA has been a stricter regu
Integer price target raised to $150 from $140 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Integer (ITGR) to $150 from $140 and keeps a Buy rating on the shares. Integer beat estimates in Q1 on EPS and organic revenue amid strength in Cardio and Vascular, and guidance for 8%-10% organic growth for fiscal 2025 was reiterated, while EPS guidance was increased, the analyst tells investors in a research note. Truist thinks the outlook leaves room for upside as the year progresses and continues to believe that the company ca
2 Reasons Nio Is a Buy Now
Nio (NYSE: NIO) is included, and despite the ongoing Chinese price war, the company has a couple of reasons for investors to remain optimistic. For many investors, it feels like a double edged sword when it comes to Nio's battery swap ambitions. Only recently, Nio saw demand for these services spike to a record high 136,720 swaps in a single day on Feb. 3.
Why Biohaven Stock Plummeted by More Than 15% Today
On Friday's news that Biohaven (NYSE: BHVN) withdrew its application for a top investigational drug from an important regulator, investors aggressively traded out of the stock. In a statement, the EMA revealed that a subsidiary of the company withdrew its application for marketing authorization for troriluzole, branded as Dazluma. Biohaven originally applied for such authorization for Dazluma toward the end of 2023.